Experience of using anti-CD 20 therapies in multiple sclerosis patients in Kenya
This retrospective, single-centre study provides real-world data on B-cell-depleting therapies in an African MS cohort. Ocrelizumab and rituximab appear to be safe, well-tolerated, and effective therapeutic options for people living with MS.
Authors
- Tejal Patel (ORCID: https://orcid.org/0000-0003-3002-8306)
- Jacqueline Mavuti
- Dilraj Sokhi (ORCID: https://orcid.org/0000-0002-8819-0851)
- Juzar Hooker (ORCID: https://orcid.org/0000-0001-7057-1843)
- Nyambane Eunice
Institutions
- Aga Khan University Hospital Nairobi (KE)
- Aga Khan University Nairobi (KE)
Publication Details
- Journal
- Frontiers in Neurology
- Published
- 2026-01-26
- DOI
- https://doi.org/10.3389/fneur.2025.1681527
- Primary Topic
- Multiple Sclerosis Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00